STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRL
  4. [Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity

Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FOSTER JAMES C reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories International Chairman, President and CEO James C. Foster received an equity award tied to the company’s common stock. He was granted 16,796 shares at a reference price of $178.61 per share, increasing his directly held stake to 279,693 shares.

According to a footnote, 100% of the unvested restricted stock units from this grant vest on March 2, 2028. Additional common stock is held indirectly through GRATs, trusts and a spouse account, and a separate footnote notes an exempt transfer of 9,220 shares from a 2025 GRAT account to direct holdings.

Positive

  • None.

Negative

  • None.
Insider FOSTER JAMES C
Role Chairman, President and CEO
Type Security Shares Price Value
Grant/Award Common Stock 16,796 $178.61 $3.00M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 279,693 shares (Direct); Common Stock — 5,423 shares (Indirect, 2024 GRAT)
Footnotes (1)
  1. 100% of the unvested restricted stock units vest on March 2, 2028. Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FOSTER JAMES C
(Last) (First) (Middle)
C/O CHARLES RIVER LABORATORIES
251 BALLARDVALE STREET
(Street)
WILMINGTON MA 01887
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman, President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/02/2026 A 16,796(1) A $178.61 279,693(2) D
Common Stock 5,423 I 2024 GRAT
Common Stock 10,780 I 2025 GRAT
Common Stock 230 I by Trust
Common Stock 750 I By Trust
Common Stock 2,250 I By Trust
Common Stock 10,000 I Held By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 100% of the unvested restricted stock units vest on March 2, 2028.
2. Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings.
/s/ James C. Foster 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CRL CEO James C. Foster report in this Form 4 filing?

James C. Foster reported receiving an equity award linked to Charles River common stock. The grant covered 16,796 shares at $178.61 per share, increasing his directly held position to 279,693 shares, plus various indirect holdings through GRATs, trusts and a spouse account.

How many Charles River (CRL) shares were granted to the CEO?

The CEO was granted 16,796 shares of Charles River common stock. This grant is recorded at a reference price of $178.61 per share and represents additional equity-based compensation on top of his existing direct and indirect ownership positions in the company.

When do the CEO’s newly reported CRL restricted stock units vest?

The unvested restricted stock units from this award vest on March 2, 2028. A filing footnote states that 100% of these units vest on that date, meaning the CEO’s ability to receive the underlying shares is tied to this long-term vesting schedule.

How many CRL shares does the CEO own directly after this transaction?

After the reported equity award, the CEO directly holds 279,693 shares of Charles River common stock. This figure reflects his direct ownership only and excludes additional shares held indirectly through GRATs, various trusts, and an account held by his spouse.

What indirect Charles River (CRL) holdings are associated with the CEO?

Indirect holdings include shares in 2024 and 2025 GRAT accounts, several trusts, and an account held by his spouse. The filing also notes an exempt transfer of 9,220 shares from the 2025 GRAT to direct holdings, reallocating ownership form without indicating an open-market trade.

Was there any exempt transfer of CRL shares reported in this Form 4?

Yes. A footnote describes an exempt transfer of 9,220 Charles River shares from a 2025 GRAT account to direct holdings. This transfer is characterized as exempt under Rule 16a-13, indicating a change in ownership form rather than a traditional market purchase or sale.